US 11912767
EGFR × CD28 multispecific antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11912767 (EGFR × CD28 multispecific antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/572, A61K39/3955